Bimatoprost is under clinical development by Laboratoires Thea and currently in Phase III for Ocular Hypertension.

H-1337 is under clinical development by D. Western Therapeutics Institute and currently in Phase II for Open-Angle Glaucoma.

Some patients with ocular hypertension who develop primary open angle glaucoma experience rapid visual field loss.

According to the company, its Phase 1/2 CLARA trial of AURN001 for corneal edema demonstrated significant dose-dependent ...

The highest dose of Aurion Biotech’s cell therapy, the main component of which recently received approval in Japan, has ...

Purpose: To review the literature regarding ocular hypertension following intravitreal antivascular endothelial growth factor therapy, and to propose a novel mechanism for the development of ...

Ocular Therapeutix, Inc ... in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Follow Ocular on its website, LinkedIn or X. The Ocular Therapeutix ...

and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which is currently in a Phase 2 clinical ...

The majority of our patients with ocular hypertension maintained IOP between 10 and 21 mm Hg across all treatment groups over time. Bai et al [4] also reported successful IOP control in their ...

and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.

and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.

This makes it an ideal site for detecting vascular and neurological changes that reflect systemic conditions. Conditions such as diabetes, hypertension, and autoimmune diseases frequently display ...